CORONA Remedies Limited — Q2 FY26
Corona Remedies delivered a solid Q2 FY26 with revenue of ₹361 crore (+15% YoY), EBITDA of ₹78.5 crore (+17.4% YoY), and PAT of ₹52 crore (+22% YoY).
bullish
high
✓ Verified against BSE filing
Claim Ledger
Did management answer the analysts?
Every material analyst question, graded on whether management actually answered it — with the verbatim exchange and quantitative claims checked against filed numbers.
83%Questions answered1Evaded / deflected12Questions auditedMixedNumbers vs filing
Answered
High priority
Current presence and growth plans in fertility segment
Asked by Alankar Garud, Kotak Institutional Equities
Management provided specific details on current position and future plans including product acquisition and team launch.
Read the exchange
Question
can you comment a bit about what exactly is your presence right now within the fertility segment... and how exactly do we plan to grow further in this segment.
Mira (management, role not stated)
we are amongst top five or six companies in women's healthcare... we acquired with bioiders about few products in the segment on infertility... we are going to launch a separate team for infertility and entering in the infertility market with this products
Partial answer
High priority
Position in newer therapeutic areas and scale expectations
Asked by Alankar Garud, Kotak Institutional Equities
Management listed therapies but did not quantify expected scale or market share targets.
no specific scale or revenue targets giventimeline vague
Read the exchange
Question
how would you describe your current position in the newer therapeutic areas of nefro CNS enco... shall we expect these therapies to be in terms of scale for us over say in the next 3 to 5 years.
Mira (management, role not stated)
we are working to develop six seven therapies today like infertility, spine, romato, CNS, dermatology, gastrointestinal... we will unlock each therapy at the right time starting with infertility... our aim is to take the leadership position in that therapy
Answered
Medium priority
R&D spend and investment plans for new therapies
Asked by Alankar Garud, Kotak Institutional Equities
Management clearly stated R&D spend will stay below 2% of revenue and team will expand modestly.
Read the exchange
Question
with us now looking at newer therapeutic areas over the next few years... is there anything different which we need to do on the R&D side whether it be beefing up our team or increasing our investments?
Mira (management, role not stated)
the percentage contribution to the R&D will remain less than 2% and today about 100 plus scientists are working in R&D we will expand little but if we grow only revenues like 15% plus that percentage less than 2% will remain less than 2%.
Answered
Medium priority
India's brand approach and how it helps growth
Asked by Yug Modi, AP Capital
Management explained the brand differentiation strategy with examples like B29.
Read the exchange
Question
I just wanted to understand our engine's brand approach in a slightly more detailed manner and how does it help in our overall growth
Mira (management, role not stated)
we try to launch the product with little niche or little differentiated manner... we try to take the road of a little differentiated manner try to put a science into it a unmet need of the patients and the medical fertility
Answered
High priority
International business strategy and geographies
Asked by Yug Modi, AP Capital
Management provided current contribution, target geographies, and product focus.
Read the exchange
Question
can you just highlight the strategy for our international business like which are the current geographies where we have a considerable presence and how do we plan to enter newer geographies
Mira (management, role not stated)
today we have about 3 and a half% contribution with the international business... we will go worldwide except US and Japan as of now to start with... Europe, UK, Australia, New Zealand, Brazil, Mexico, Asia and CIS Russia
Answered
High priority
Productivity (PCPM) for domestic business and ramp-up plans
Asked by Rahul Jivani, IIL Capital Services Limited
Management gave current PCPM, breakdown by tenure, and noted productivity increases with maturity.
Read the exchange
Question
can you talk about the productivity or the PCPM for the domestic business which versus some of the other chronic peers is slightly on the lower side. So how do you see this productivity ramping up for us over the next 3 to four year period
Mira (management, role not stated)
corona's PCPM per capita per month is about 3.9 months about four lakhs rupees... productivity vise from 2.5 lakh to 8 lakh from the people who have been joined you know 6 to 9 years range
Answered
High priority
MR addition plans and productivity targets
Asked by Rahul Jivani, IIL Capital Services Limited
Management provided specific MR growth rate and financial targets.
Read the exchange
Question
how many reps do you plan to add every year and then from a 3 to four year perspective do we have any target productivity in mind
Mira (management, role not stated)
we have decided to expand these MR numbers by 5 to 7% on year on year... our endeavor is to grow on 15% on revenue and 20% on PAT
Answered
High priority
Update on hormonal plant and EU GMP approval timeline
Asked by Rahul Jivani, IIL Capital Services Limited
Management gave specific timelines for commercial start and WH approval.
Read the exchange
Question
can you just update us in terms of progress at that plant? when do we expect to receive the WH and the EU GMP approvals for that plant?
Mira (management, role not stated)
we are now going to kickstart the commercial by the Q2 end of Q2 or early of Q3 of FY27... by Q4 of FY27 we're expecting about WH and by that time we will try to take EUGMP inspection
Partial answer
Medium priority
M&A strategy and evaluation of further assets
Asked by Rahul Jivani, IIL Capital Services Limited
Management acknowledged evaluation but provided no specifics on potential deals.
no specific details on targets or valuationdeferred to future
Read the exchange
Question
how you are seeing the M&A market in terms of acquisitions in India? So are you evaluating any further assets to diversify your portfolio in the India business.
Mira (management, role not stated)
we are constantly evaluating it... we are looking at two three interesting opportunities but nothing concrete as of now after Zidus buyer our first focus is to make this acquisition more meaningful
Answered
Medium priority
Seasonality in business: H2 vs H1 margins and revenue
Asked by Niharika Agarwal, Incred Asset Management
Management provided clear split and explained minor seasonal variations.
Read the exchange
Question
could you help us understand the seasonality in your business? Is H2 typically stronger than H1 in terms of margins or revenue?
Mira (management, role not stated)
more or less it is 50/50 but 100 basis point minus in the first half versus 100 basis point... Q3 slightly lesser because of festive season but also 25 to 27% on quarter on quarter
Evasive
High priority
Sustainability of 22-23% margin band for FY27
Asked by Niharika Agarwal, Incred Asset Management
Management avoided answering margin sustainability directly, instead reiterated PAT growth target.
did not confirm or deny margin bandreframed to PAT growth target
Read the exchange
Question
given the stabilization in raw material costs and your product mix shift towards chronic therapies. Is 22 to 23% a sustainable margin band for FY27 or do you plan to reinvest the gains into marketing or field force?
Mira (management, role not stated)
our endeavor is about 20% PAT or EPS growth year on year for next four years. We have a plan in place till FY 29
Answered
Medium priority
Geographic mix and urban/rural strategy for specialist approach
Asked by A (first name only), JM Financial
Management explained the evolving market and confirmed continued focus on specialist segment.
Read the exchange
Question
in terms of the geographic presence where also this approach is applicable in terms of the city urban and rural mix. So you expect we need to change a bit there considering we have well above now 1000 cr in terms of size of the business.
Mira (management, role not stated)
the market shift has been happening in the specialist in each category from semi-urban to metro is increasing heavily... our focus will remain same on the middle of the pyramid specialist
Quantitative claims vs filed numbers
| Claim | Management said | Filing | Verdict |
|---|---|---|---|
| Revenue growth target 15% | 15% | 15% | Matches filing |
| PAT growth target 20% | 20% | 22% | Understated vs filing |
Filed figures sourced from Screener.in. Claims within a small tolerance of the filing are marked “matches filing”.